Data Presentations at ADA 82nd Scientific Sessions
![](https://tracker.prod.prod.rnssubmit.com/track.live-rns/4392185_6b796387bafb461f41df962c3713dcaf.png)
("Renalytix" or the "Company")
Renalytix held Two Data Presentations on KidneyIntelX at
Real-world clinical utility in 1,112 patients tested with KidneyIntelX
KidneyIntelX stratification for cardiovascular risk in 1,278 diabetic kidney disease patients
The ePoster, "Clinical Utility of KidneyIntelX on Patients with Early-Stage Diabetic Kidney Disease-A Real-World Evidence Study" was the first time
A second oral presentation, "
"We've seen the
The ePoster and oral presentation abstracts are available at the 2022 ADA Scientific Sessions Online Planner.
KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix. Mount Sinai and
About Kidney Disease
Kidney disease is a public health epidemic affecting over 850 million people globally.1 The
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosisTM for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed KidneyIntelX to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3 through its KidneyIntelXTM laboratory-developed test. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
About KidneyIntelXTM
KidneyIntelXTM is a laboratory-developed test demonstrated to be a highly reliable, bioprognosticTM methodology, that yields a simple-to-understand, custom risk score, predicting which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio- and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has a demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). KidneyIntelX has also received Breakthrough Device Designation from the
About the
The
Sources
2https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
3https://www.cdc.gov/kidneydisease/basics.html
For further information, please contact:
|
||||
|
Via Walbrook PR |
|||
|
|
|||
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|||
|
|
|||
|
|
|||
|
Tel: 020 7597 4000 |
|||
|
|
|||
|
|
|||
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|||
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|||
|
|
|||
|
|
|||
|
Tel: 415-389-6400 or investors@renalytix.com |
|||
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits, including economic savings, of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the